JLE

Hépato-Gastro & Oncologie Digestive

MENU

Towards personalized medicine with anti-TNF? Not yet… Volume 31, issue 1, January 2024

Authors
CHU de Saint-Étienne, Service d’hépato-gastro-entérologie, Avenue Albert Raimond, 42270 Saint-Priest-en-Jarez
* Correspondance : X. Roblin

There is a link between the presence of the HLA DQA1-05 allele and the development of anti-TNF antibodies. Testing for the HLA DQA1-05 variant makes it possible to isolate patients at high immunogenic risk under anti-TNF therapy, but sensitivity and specificity are insufficient to propose precise algorithms based on the result. This test remains a decision-making tool. Elevated IFX clearance identifies patients at greatest risk of colectomy in the follow-up of severe acute colitis.